[go: up one dir, main page]

AU9024591A - Biphenylalkyl xanthine compounds for treatment of cardiovascular disorders - Google Patents

Biphenylalkyl xanthine compounds for treatment of cardiovascular disorders

Info

Publication number
AU9024591A
AU9024591A AU90245/91A AU9024591A AU9024591A AU 9024591 A AU9024591 A AU 9024591A AU 90245/91 A AU90245/91 A AU 90245/91A AU 9024591 A AU9024591 A AU 9024591A AU 9024591 A AU9024591 A AU 9024591A
Authority
AU
Australia
Prior art keywords
biphenylalkyl
treatment
cardiovascular disorders
xanthine compounds
xanthine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU90245/91A
Inventor
Philippe R Bovy
Timothy S Chamberlain
Joe T Collins
Brian K Gheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of AU9024591A publication Critical patent/AU9024591A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Connections Arranged To Contact A Plurality Of Conductors (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU90245/91A 1990-10-25 1991-10-16 Biphenylalkyl xanthine compounds for treatment of cardiovascular disorders Abandoned AU9024591A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60365390A 1990-10-25 1990-10-25
US603653 1990-10-25

Publications (1)

Publication Number Publication Date
AU9024591A true AU9024591A (en) 1992-05-26

Family

ID=24416375

Family Applications (1)

Application Number Title Priority Date Filing Date
AU90245/91A Abandoned AU9024591A (en) 1990-10-25 1991-10-16 Biphenylalkyl xanthine compounds for treatment of cardiovascular disorders

Country Status (3)

Country Link
AU (1) AU9024591A (en)
CA (1) CA2055129A1 (en)
WO (1) WO1992007852A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU653364B2 (en) * 1990-09-26 1994-09-29 Beecham Group Plc Xanthine derivatives

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990095A (en) 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
SE9903028D0 (en) 1999-08-27 1999-08-27 Astra Ab New use
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
IL94390A (en) * 1989-05-30 1996-03-31 Merck & Co Inc Di-substituted imidazo fused 6-membered nitrogen-containing heterocycles and pharmaceutical compositions containing them
IL96019A0 (en) * 1989-10-31 1991-07-18 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
EP0430300A3 (en) * 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU653364B2 (en) * 1990-09-26 1994-09-29 Beecham Group Plc Xanthine derivatives

Also Published As

Publication number Publication date
WO1992007852A1 (en) 1992-05-14
CA2055129A1 (en) 1992-06-21

Similar Documents

Publication Publication Date Title
AU4525396A (en) Process for the preparation of perfluorocarbons
AU2351492A (en) Process for the preparation of middle distillates
AU7903091A (en) N-substituted-1,2,4-triazolone compounds for treatment of cardiovascular disorders
AU9024591A (en) Biphenylalkyl xanthine compounds for treatment of cardiovascular disorders
EP0510503A3 (en) Process for the treatment of surfaces
HU9301985D0 (en) Process for the preparation of wort
AU8656491A (en) 1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
AU1142192A (en) Process for the preparation of 13c-labelled compounds
GB9323088D0 (en) Novel process for the preparation of benzylformimidate
AU8463691A (en) Processes for the preparation of nitrogen-containing compounds
HUT69309A (en) Process for the preparation of 2-alkoxymethyl-acrolein
AU8457591A (en) Process for the preparation of carbapenem compounds
AU8251891A (en) Process for the preparation of 1-alkylisoquinoline derivatives
AU8516891A (en) Acid treatment for decaffeination of coffee
AU8036291A (en) Process for the preparation of 1-hydroxymethylpyrazoles
AU1235992A (en) Process for separation of two solid components
EP0537589A3 (en) Process for the preparation of dinitro- and diaminophenoxy compounds
EP0518013A3 (en) Process for the preparation of 1-alkoxy-2-dialkylaminoethanes
AU2882592A (en) Methods for treatment of hyperlipidemia using azaspiranes
AU2297192A (en) Optically pure s(-) nadolol for treatment of cardiovascular disorders
AU2875092A (en) Methods for the treatment of hyperlipidemia using azaspiranes
AU1306992A (en) Process for the preparation of n-alkylsufonamides
AU640818B2 (en) Process for the preparation of aminopyrimidines
EP0548618A3 (en) Process for the preparation of 2-aminobenzaldehydes
EP0534249A3 (en) Process for the preparation of 3-phenyl-2-propenones